Category Ranking
98%
Total Visits
921
Avg Visit Duration
2 minutes
Citations
20
Article Abstract
Background/aim: The approval of first-line nivolumab plus chemotherapy marks a breakthrough in treating human epidermal growth factor receptor 2 (HER2)-negative unresectable advanced gastric and gastroesophageal junction (G/GEJ) cancer. This study aimed to evaluate the impact of nivolumab plus chemotherapy on conversion therapy in clinical stage (cStage) IVB HER2-negative G/GEJ adenocarcinoma.
Patients And Methods: Patients with cStage IVB HER2-negative G/GEJ adenocarcinoma who underwent systemic chemotherapy at Hyogo Medical University Hospital from January 2017 to March 2023 were included. Nivolumab plus chemotherapy was initiated following its approval in Japan in November 2021. Conversion surgery (CS) was performed when distant metastases had disappeared, except for resectable liver metastases.
Results: In total, 103 patients were eligible: 28 received nivolumab plus chemotherapy, and 75 received chemotherapy as first-line treatment. The conversion rate in the nivolumab plus chemotherapy group was significantly higher than that in the chemotherapy group (28.6% 8.0%, =0.011). Multivariate analysis revealed a significant association between first-line nivolumab plus chemotherapy and undergoing CS [odds ratio=3.540, 95% confidence interval (CI)=1.059-12.157]. R0 resection was achieved in all eight patients who underwent CS, and delayed immune-related adverse events did not occur perioperatively. In the nivolumab plus chemotherapy group, the median survival time in patients who underwent CS was significantly longer than that in patients treated with chemotherapy alone [not reached (95%CI=22.7-not reached) 11.8 months (95%CI=5.1-33.3), =0.035].
Conclusion: First-line nivolumab plus chemotherapy increased the conversion rate compared with chemotherapy in patients with cStage IVB HER2-negative G/GEJ adenocarcinoma. CS following nivolumab plus chemotherapy was safe, and patients who underwent CS survived longer than those who received chemotherapy alone.
Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.21873/anticanres.17583 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Two Cases of Primary Melanoma of the Uterine Cervix.
Am J Case Rep
September 2025
Department of Obstetrics and Gynecology, Taipei Medical University Hospital, Taipei, Taiwan.
BACKGROUND This study reports on 2 cases of cervical melanoma with similar presentations but at different stages, and the treatment strategy varied accordingly, and we review the literature on the characteristics, diagnosis, and management of cervical melanoma. CASE REPORT Case 1: A 69-year-old woman with abnormal vaginal bleeding was diagnosed with advanced cervical melanoma, staged as International Federation of Gynecology and Obstetrics (FIGO) Stage IVB, involving multiple metastases. Despite chemoradiotherapy and immunotherapy (nivolumab), the disease progressed rapidly, and the patient died 4 months after diagnosis.
View Article and Find Full Text PDFPerioperative nivolumab or nivolumab plus ipilimumab in resectable diffuse pleural mesothelioma: a phase 2 trial and ctDNA analyses.
Nat Med
September 2025
Sidney Kimmel Comprehensive Cancer Center, Johns Hopkins University School of Medicine, Baltimore, MD, USA.
Immune checkpoint blockade (ICB) is standard of care in advanced diffuse pleural mesothelioma (DPM), but its role in the perioperative management of DPM is unclear. In tandem, circulating tumor DNA (ctDNA) ultra-sensitive residual disease detection has shown promise in providing a molecular readout of ICB efficacy across resectable cancers. This phase 2 trial investigated neoadjuvant nivolumab and nivolumab/ipilimumab in resectable DPM along with tumor-informed liquid biopsy residual disease assessments.
View Article and Find Full Text PDFDrug Reaction With Eosinophilia and Systemic Symptoms (DRESS) Following Conversion Surgery for Esophageal Cancer: A Case Report.
Cureus
August 2025
Department of Gastrointestinal and Pediatric Surgery, Division of Reparative Medicine, Institute of Life Sciences, Graduate School of Medicine, Mie University, Tsu, JPN.
Conversion surgery is increasingly used for initially unresectable esophageal cancer patients responding to induction therapy. The integration of immune checkpoint inhibitors (ICIs) into standard chemotherapy regimens is expected to increase the number of patients undergoing this approach. However, ICIs can cause immune-related adverse events (irAEs), which are often difficult to diagnose in the postoperative setting.
View Article and Find Full Text PDFEfficacy of Immune Checkpoint Inhibitors in the Treatment for Head and Neck Cancer Patients: A Systematic Review and Network Meta-Analysis.
Oncol Res
September 2025
Department of Pathology, Changzhi Medical College, Changzhi, 046000, China.
Objectives: Checkpoint inhibitors have significantly improved outcomes in a number of malignancies. To determine the most effective course of treatment for head and neck squamous cell carcinoma (HNSCC), this systematic review evaluated the efficacy of several therapeutic approaches based on immune checkpoint inhibitors (ICIs).
Methods: A comprehensive evaluation of the literature was conducted, looking at randomized controlled trials (RCTs) that were published in Embase, PubMed, and the Cochrane Central Register of Controlled Trials since database establishment.
Successful Management of Tumor Lysis Syndrome Following Enfortumab Vedotin Plus Pembrolizumab Therapy in Metastatic Urothelial Carcinoma: A Case Report.
IJU Case Rep
September 2025
Department of Urology Kochi Medical School, Kochi University Nankoku Kochi Japan.
Introduction: Enfortumab vedotin plus pembrolizumab (EV + ) shows high efficacy in metastatic urothelial carcinoma (mUC), potentially increasing tumor lysis syndrome (TLS) risk.
Case Presentation: A 64-year-old man with mUC underwent surgery and adjuvant nivolumab after neoadjuvant chemotherapy. Five months post-surgery, EV + was initiated for recurrence with distant metastasis.